NAT-CITALOPRAM 20 MG
CITALOPRAM (CITALOPRAM HYDROBROMIDE) : 20 MG · DIN 02409011 · NATCO PHARMA (CANADA) INC
Health Canada status: CANCELLED POST MARKET
What is NAT-CITALOPRAM?
NAT-CITALOPRAM 20 MG contains CITALOPRAM (CITALOPRAM HYDROBROMIDE) : 20 MG. It is listed in the Health Canada Drug Product Database under DIN 02409011, held by NATCO PHARMA (CANADA) INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 10-Feb-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is NAT-CITALOPRAM used for?
Symptomatic relief of depressive illness in adults.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02409011 |
|---|---|
| Brand name | NAT-CITALOPRAM |
| Generic / active ingredient | CITALOPRAM (CITALOPRAM HYDROBROMIDE) : 20 MG |
| Manufacturer | NATCO PHARMA (CANADA) INC |
| Strength | 20 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N06AB04 CITALOPRAM |
| AHFS class | 28:16.04.20 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 10-Feb-2025 |
| Original market date | 2014-02-12 00:00:00 |
How is it administered?
Administered as a single oral dose, morning or evening, with or without food. Max dose 40 mg/day. Lower doses for elderly and hepatic impairment. Gradual tapering required for discontinuation.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15-30°C (implied by standard USP/Part I summary, though specific section 30 text is missing).
How is it supplied?
Not explicitly detailed in provided text (referenced in Section 30, but text cuts off). Standard strengths: 10mg, 20mg, 40mg.
Contraindications
Hypersensitivity; Monoamine Oxidase Inhibitors (MAOIs); Pimozide; Patients with known QT interval prolongation or congenital long QT syndrome.
Warnings and precautions
Potential for suicidal ideation/behavior; QT prolongation and Torsades de Pointes; Serotonin Syndrome; Abnormal bleeding; Bone fracture risk; Discontinuation symptoms.
Is CITALOPRAM in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by JAMP PHARMA CORPORATION, last seen 03 Aug 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N06AB04 CITALOPRAM. 55 of 149 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-CITALOPRAM | 10 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02374617 |
| AG-CITALOPRAM | 20 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02339390 |
| AG-CITALOPRAM | 40 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02339404 |
| AG-CITALOPRAM TABLETS | 10 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02513676 |
| AG-CITALOPRAM TABLETS | 20 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02513684 |
| AG-CITALOPRAM TABLETS | 30 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02543060 |
| AG-CITALOPRAM TABLETS | 40 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02513692 |
| APO-CITALOPRAM | 20 MG | TABLET | APOTEX INC | MARKETED | DIN 02246056 |
| APO-CITALOPRAM | 40 MG | TABLET | APOTEX INC | MARKETED | DIN 02246057 |
| AURO-CITALOPRAM | 20 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02275562 |
Who else supplies CITALOPRAM worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CITALOPRAM appears in 433 registered pack listings across 15 markets, published on 13 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.